Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Ada Dona', PhD, Domenico Viola, Enrico Caserta, PhD, Francesca Besi, PhD, James F Sanchez, PhD, Guido Marcucci, MD, Jonathan J Keats, PhD, Amrita Y. Krishnan, MD, Matt Coffey, PhD, Douglas W. Sborov, MDMSc, Gerard Nuovo, MD, Craig C Hofmeister, MDMPH, Flavia Pichiorri, PhD

Blood (2019) 134 (Supplement_1): 1816.

https://doi.org/10.1182/blood-2019-128740

Published: 2019

Journal Articles

Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses

Craig C Hofmeister, MDMPH, Douglas W. Sborov, MD MS, Domenico Viola, Ada Dona, Gerald J Nuovo, PhD, Don M. Benson, Jr., MD PhD, Sagar Lonial, MD, Jonathan L Kaufman, MD, Ajay K Nooka, MD MPH, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 2655.

https://doi.org/10.1182/blood-2018-99-113500

Published: 2018

Journal Articles

A Decade of Anti-Myeloma Vaccine Development through Early Phase Trials: A Systematic Review

Nadia Carenina Nunes Cavalcante Parr, MD, Muhammad Junaid Tariq, MD, Muhammad Usman, MD, Muhammad Asad Fraz, MD, Ali Younas Khan, MD, Sharoon Samuel, MBBS, Awais Ijaz, MD, Malik Qistas Ahmad, MD MBBS, Muhammad Jahanzeb Khalil, MD, Muhammad Yasir, MD, Saher Nasir Amin, MD, Ahmad Safdar, Abdul Rafae, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5635.

https://doi.org/10.1182/blood-2018-99-115922

Published: 2018

Journal Articles

Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma

Shariful Islam, Claudia M Espitia, Ning Qu, MD PhD, Daniel Persky, MD, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2018) 132 (Supplement 1): 2941.

https://doi.org/10.1182/blood-2018-99-119152

Published: 2018

Journal Articles

Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

Kevin R Kelly, MD PhD, Claudia M Espitia, Weiguo Zhao, Kaijin Wu, Valeria Visconte, PhD, Faiz Anwer, MD, Christine M Calton, PhD, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2017) 130 (Supplement 1): 3137.

https://doi.org/10.1182/blood.V130.Suppl_1.3137.3137

Published: 2017

Journal Articles

Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Kevin R. Kelly, MD PhD, Kaijin Wu, PhD, Denice Tsao-Wei, Susan Groshen, Timothy Junius Triche, Jr., PhD, Ann Mohrbacher, Grace Chang, MD, Donna Fernando, Imran N Siddiqi, MD PhD, Matt Coffey, George Gill, Amy Lee, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2016) 128 (22): 4507.

https://doi.org/10.1182/blood.V128.22.4507.4507

Published: 2016

Journal Articles

Exploring the Possibility of Using Herpes Simplex Virus in Oncolytic Virotherapy of Multiple Myeloma

Jayeeta Ghose, Luke Russell, Enrico Caserta, Ramasamy Santhanam, Alena Cristina Jaime-Ramirez, Domenico Viola, Amrita Krishnan, Craig C Hofmeister, Balveen Kaur, Flavia Pichiorri, PhD

Blood (2016) 128 (22): 4467.

https://doi.org/10.1182/blood.V128.22.4467.4467

Published: 2016

Journal Articles

Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses.

Valentina Marchica, Gaetano Donofrio, PhD, Rosanna Vescovini, PhD, Giulia Tebaldi, Alfonso Rosamilia, Daniela Guasco, Paola Storti, PhD, Marina Bolzoni, PhD, Federica Costa, Chiara Schifano, MSc, Sabrina Bonomini, MSc, Fabrizio Accardi, MD, Francesco Piazza, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2016) 128 (22): 2093.

https://doi.org/10.1182/blood.V128.22.2093.2093

Published: 2016

Journal Articles

A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma

Kevin R. Kelly, MD PhD, Claudia M. Espitia, Weiguo Zhao, Valeria Visconte, PhD, Matt Coffey, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2016) 128 (22): 3960.

https://doi.org/10.1182/blood.V128.22.3960.3960

Published: 2016

Journal Articles

Natural Killer Cells Activated By Oncolytic Reovirus Enhance Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity in an in Vitro and In Vivo Model of Colorectal Cancer

Xing Zhao, PhD, Narendiran Rajasekaran, PhD, Cariad Chester, BA, Atsushi Yonezawa, PhD, Suparna Dutt, PhD, Matt Coffey, Zhixu He, MDPhD, Holbrook E Kohrt, MD PhD

Blood (2015) 126 (23): 3439.

https://doi.org/10.1182/blood.V126.23.3439.3439

Published: 2015

Journal Articles

In Vitro Stromal Co-Culture Model For The Evaluation Of Reovirus Oncolytic Therapy For Refractory Pediatric Leukemia

Gaya Narendran, Matthew F. Clarkson, Randal Johnston, PhD

Blood (2013) 122 (21): 5407.

https://doi.org/10.1182/blood.V122.21.5407.5407

Published: 2013

Journal Articles

A Phase 1 Trial Of Reolysin Alone In Patients With Refractory Or Relapsed Multiple Myeloma

Douglas W. Sborov, MD, Gerard Nuovo, PhD, Andrew Stiff, BS, Thomas Mace, PhD, Gregory Lesinski, PhD, MPH, Don M. Benson, Jr., MD, PhD, Yvonne A Efebera, MD, Ashley E. Rosko, MD, Flavia Pichiorri, PhD, Craig C Hofmeister, MD

Blood (2013) 122 (21): 3208.

https://doi.org/10.1182/blood.V122.21.3208.3208

Published: 2013

Journal Articles

Understanding The Differential Response Of Multiple Myeloma To Reovirus Treatment

Andrew Stiff, BS, Joseph Badway, B.S., Gerard Nuovo, PhD, Douglas W. Sborov, MD, Emily M Smith, BS, Tiffany Talabere, Craig C Hofmeister, MD, Flavia Pichiorri, PhD

Blood (2013) 122 (21): 3232.

https://doi.org/10.1182/blood.V122.21.3232.3232

Published: 2013

Journal Articles

Preclinical Evaluation of Oncolytic Reovirus in Targeted Therapeutics for High-Risk Pediatric Leukemia

Matthew F. Clarkson, Aru Narendran, MD, PhD, Randal N. Johnston, PhD

Blood (2012) 120 (21): 3571.

https://doi.org/10.1182/blood.V120.21.3571.3571

Published: 2012

Journal Articles

Human mast cell activation with virus-associated stimuli leads to the selective chemotaxis of natural killer cells by a CXCL8-dependent mechanism

Sarah M. Burke, Thomas B. Issekutz, Karkada Mohan, Patrick W. K. Lee, Maya Shmulevitz, Jean S. Marshall

Blood (2008) 111 (12): 5467–5476.

https://doi.org/10.1182/blood-2007-10-118547

Published: 2008

Journal Articles

Treatment with Intermediate Subviral Particles Overcomes Resistance to Reovirus Induced Oncolysis in Mantle Cell Lymphoma Cell Lines.

Gwyn Bebb, BMBCh, PhD, Huong Muzik, BSc, Tom Alain, BSc, Karen Dong, BSc, Chandini Thirukkamaran, PhD, Peter Forsyth, MD, PhD, Don Morris, MD, PhD

Blood (2005) 106 (11): 2417.

https://doi.org/10.1182/blood.V106.11.2417.2417

Published: 2005

Journal Articles

Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation

Chandini M. Thirukkumaran, Joanne M. Luider, Douglas A. Stewart, Tina Cheng, Sasha M. Lupichuk, Michael J. Nodwell, James A. Russell, Iwona A. Auer, Donald G. Morris

Blood (2003) 102 (1): 377–387.

https://doi.org/10.1182/blood-2002-08-2508

Published: 2003

Journal Articles

Reovirus therapy of lymphoid malignancies

Tommy Alain, Kensuke Hirasawa, Kelly J. Pon, Sandra G. Nishikawa, Stefan J. Urbanski, Yvonna Auer, Joanne Luider, Anita Martin, Randal N. Johnston, Anna Janowska-Wieczorek, Patrick W. K. Lee, Anna E. Kossakowska

Blood (2002) 100 (12): 4146–4153.

https://doi.org/10.1182/blood-2002-02-0503

Published: 2002

NARROW

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses

A Decade of Anti-Myeloma Vaccine Development through Early Phase Trials: A Systematic Review

Oncolytic Reovirus Is an Effective Treatment for Histone Deacetylase Inhibitor Resistant T-Cell Lymphoma

Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Exploring the Possibility of Using Herpes Simplex Virus in Oncolytic Virotherapy of Multiple Myeloma

Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses.

A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma

Natural Killer Cells Activated By Oncolytic Reovirus Enhance Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity in an in Vitro and In Vivo Model of Colorectal Cancer

In Vitro Stromal Co-Culture Model For The Evaluation Of Reovirus Oncolytic Therapy For Refractory Pediatric Leukemia

A Phase 1 Trial Of Reolysin Alone In Patients With Refractory Or Relapsed Multiple Myeloma

Understanding The Differential Response Of Multiple Myeloma To Reovirus Treatment

Preclinical Evaluation of Oncolytic Reovirus in Targeted Therapeutics for High-Risk Pediatric Leukemia

Human mast cell activation with virus-associated stimuli leads to the selective chemotaxis of natural killer cells by a CXCL8-dependent mechanism

Treatment with Intermediate Subviral Particles Overcomes Resistance to Reovirus Induced Oncolysis in Mantle Cell Lymphoma Cell Lines.

Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation

Reovirus therapy of lymphoid malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only